CJC-1295
CJC-1295 is lab-made[1]. It is a GHRH peptide built to bind albumin[1]. GHRH means growth hormone-releasing hormone[1]. Forum reports describe claimed use for weight loss, muscle, skin, sleep and injury healing[2]. Two randomized trials in healthy adults found mean GH rose twofold to tenfold for at least 6 days[3]. Mean IGF-I rose 1.5-fold to threefold for 9 to 11 days[3]. The exact-name PubMed clinical-trial search returned hormone papers, not muscle, recovery, sleep or fat-loss trials[4]. The US FDA lists injection-site reactions, headache, diarrhea, flushing and heart-rate increases[5]. FDA treats DAC and no-DAC forms as different active moieties[5].
Funded by ConjuChem, Inc. (DOI 10.1210/jc.2005-1536; funding checked 2026-09-05).
What is CJC-1295?
Jetté and colleagues built CJC-1295 from a GHRH fragment and tested it in rats and pituitary cells[1]. Its albumin-binding design is why many searches ask about DAC. FDA says the DAC part is an MPA-bound lysine group that lets the peptide bind serum albumin in the body[5].
The public claims are broader than the trial record. Van Hout and Hearne found forum talk about weight loss, muscle, skin, sleep, and injury healing[2]. The controlled human papers here tested hormone response and GH pulses, not those end points.
What has been published in humans?
The clearest human result is hormone change. GH rose[3]. IGF-I rose[3]. That is a clear signal. It is not the same as a gym result. Teichman et al. reported two randomized, placebo-controlled trials in healthy adults. Ionescu and Frohman then measured GH pulses one week after one injection. A later protein paper reused samples from 11 of those men.
| Source | People | Measured result | Limit | Funder note | Checked |
|---|---|---|---|---|---|
| [3] | Two healthy-adult trials lasting 28 and 49 days | One injection produced dose-dependent mean plasma GH increases of twofold to tenfold for 6 days or more[3]. Mean IGF-I increased 1.5-fold to threefold for 9 to 11 days. Multiple doses kept mean IGF-I above baseline for up to 28 days. | The outcome measures were GH, IGF-I, and pharmacokinetic parameters. | Funded by ConjuChem, Inc. (DOI 10.1210/jc.2005-1536; funding checked 2026-09-05). The OUP article page lists ConjuChem affiliations for Lawrence, Gagnon, and Castaigne. The US FDA says the study substance was manufactured by ConjuChem. | 2026-08-30 |
| [10] | 12 healthy 20- to 40-year-old men | One week after 60 or 90 microg/kg, trough GH rose 7.5-fold, mean GH rose 46%, and IGF-I rose 45%[10]. GH pulse frequency and pulse magnitude were unaltered. | The paper measured overnight hormone profiles, not body-composition outcomes. | PubMed XML lists NIH grant M01-RR-13987. | 2026-08-30 |
| [11] | Stored sera from 11 healthy young adult men | Five protein spots changed one week after CJC-1295, including apolipoprotein A1 and transthyretin forms that decreased and beta-hemoglobin or albumin/immunoglobulin fragments that increased[11]. One changed spot had a linear relationship with IGF-I. | This was a biomarker analysis of earlier samples, not an independent treatment trial. | PubMed XML lists NIH grants R01 AG019899 and R15 DK075436. | 2026-08-30 |
| [12] | 120 people with HIV-associated visceral obesity in the registry record | The trial registry names CJC 1295 as the drug and ConjuChem as sponsor[12]. The record is terminated and posts no results. | The registry gives no stopping reason and no result table. | Sponsor listed as ConjuChem. | 2026-08-30 |
The PubMed clinical-trial search returned only those two hormone papers[4]. No controlled CJC-1295 plus ipamorelin paper is cited here. The forum and Reddit accounts below show what people report. They do not replace a controlled outcome study.
What does the evidence say about CJC-1295 with ipamorelin?
CJC-1295 plus ipamorelin is a major reader question. No trial cited here tested CJC-1295 plus ipamorelin. The exact-name PubMed trial search returned PMID 17018654 and PMID 16352683[4]. Those papers measured CJC-1295 hormone response, not the pair.
Opened user reports do discuss the pair. One ExcelMale user described products labelled CJC-1295 without DAC and ipamorelin, then later described adding a DAC-labelled exposure[19]. One Reddit thread described CJC/Ipa experiences[20]. These are self-selected reports. They are not lab verification or controlled trial evidence.
What benefits has CJC-1295 been studied or reported for?
The human papers support hormone response as the clearest measured finding. Teichman et al. reported dose-dependent GH and IGF-I increases after CJC-1295 in healthy adults[3]. Ionescu and Frohman reported higher trough GH, mean GH, and IGF-I one week after one injection[10]. Those papers did not measure strength, fat loss, skin, sleep, or recovery.
Forum evidence adds the public-use claims. Van Hout and Hearne found CJC-1295 forum talk about weight loss, muscle, skin, sleep, and injury healing[2]. The opened Reddit thread below includes positive self-reports about energy, recovery, sleep, body change, skin, cognition, and mood[20]. The page keeps those reports separate from the measured GH and IGF-I results.
What side effects and safety findings were recorded?
The healthy-adult studies reported strong GH and IGF-I responses first. The same evidence record also carries the short-window adverse findings. The table keeps both parts in view. The US FDA's 2024 staff briefing adds an unpublished HIV-lipodystrophy study account and separates that account from the published healthy-adult papers.
| Source | Recorded safety finding | Funding note | Checked |
|---|---|---|---|
| [3] | The abstract reports no serious adverse reactions after CJC-1295 in the two healthy-adult trials[3]. | Funded by ConjuChem, Inc. (DOI 10.1210/jc.2005-1536; funding checked 2026-09-05). ConjuChem affiliations appear on the OUP article page. | 2026-08-30 |
| [5] | FDA summarizes Study 1 as 33 of 35 active participants with any adverse event and 2 of 7 placebo participants with any adverse event[5]. FDA lists about 70% injection-site reactions, almost 30% transient urticarial rash, 63% headache, 43% diarrhea, and 30% systemic vasodilatory reactions in active participants. | US regulator review of cited literature and submitted information. | 2026-08-30 |
| [5] | FDA summarizes Study 2 as injection-site reactions in all active participants. Flushing ranged from 40% after lower-dose injections to 100% after higher-dose injections. One subject had transient involuntary leg muscle contractions and some loss of coordination. Two subjects had transient dizziness and hypotension. | US regulator review of cited literature and submitted information. | 2026-08-30 |
| [10] | The 12-man paper reported no serious adverse events[10]. FDA's review of the same paper notes dose-dependent heart-rate increase and transient injection-site redness or tenderness. | PubMed XML lists NIH grant M01-RR-13987. | 2026-08-30 |
| [5] | FDA describes anecdotal reports of an unpublished HIV-lipodystrophy study in which one subject died after chest discomfort and an ECG consistent with acute myocardial infarction. FDA says the death was attributed to coronary artery disease with plaque rupture and occlusion. | US regulator source; the briefing describes the HIV study reports as anecdotal. | 2026-08-30 |
| [13] | FDA's current withdrawn-nominations table lists CJC-1295 and names immunogenicity, peptide impurities, API characterization, increased heart rate, systemic vasodilatory reaction, and limited clinical data[13]. | US regulator source; not an approval record and not a new trial. | 2026-08-30 |
These rows describe named studies, FDA review, and FDA's current US compounding table. They do not give a rate for current grey-market products. The vial-testing section is the separate place for measured product contents.
What dosage information do sources report for CJC-1295?
These are source reports. They are not site advice. A named source matters more than a vial label. The rows show what named studies, a regulator briefing, a registry, or opened user reports administered or described. No row turns a number into a plan.
| Source | Reported amount | Source type | What that means here | Checked |
|---|---|---|---|---|
| [3] | The abstract says Study 1 used four ascending single subcutaneous doses and Study 2 used two or three weekly or biweekly doses[3]. | Human randomized trials | The abstract gives the route and schedule shape but not every arm amount. | 2026-08-30 |
| [5] | The US FDA staff briefing reports Study 2 groups using 30 microg/kg on days 0 and 14, 60 microg/kg on days 0 and 14, 30 microg/kg on days 0, 7, and 14, or 20 microg/kg on days 0, 7, and 14[5]. | Regulator briefing of published healthy-adult trial | These are study arms in healthy adults, not a current product label. | 2026-08-30 |
| [10] | The 12-man pulsatility study used one injection of either 60 or 90 microg/kg[10]. | Human hormone-profile study | The study sampled GH every 20 minutes overnight before dosing and one week later. | 2026-08-30 |
| [12] | The registry names CJC 1295 as the drug but posts no arm dose and no results[12]. | Clinical-trial registry | It adds a registered population and sponsor, not a usable amount. | 2026-08-30 |
| [14] | The exact DailyMed search returned zero current US labels for CJC-1295[14]. | US product-label search | No approved-product dose is supplied by this exact search. | 2026-08-30 |
| [19] | One user reported 100 mcg CJC with ipamorelin, then 100 mcg CJC at three daily timings, later 200 mcg each morning and evening, and later a 2 mg weekly CJC-1295 DAC exposure with 400 mcg no-DAC plus 400 mcg ipamorelin at night[19]. | Opened user-report thread | This is one self-reported account; the products were not lab verified in the thread. | 2026-08-30 |
The dosage-search demand is large because CJC-1295 is often sold as a vial before a reader has a clean answer. The safest useful answer is therefore a ledger of named-source amounts. It does not collapse study arms, registry gaps, and forum accounts into one "usual" dose.
What do animal and laboratory studies add?
Animal and lab work explains the long-action design. It also keeps DAC-specific safety signals visible. These findings are not body-composition trials.
| Source | Finding | Limit | Funder note | Checked |
|---|---|---|---|---|
| [1] | CJC-1295 produced a fourfold GH area-under-the-curve increase over 2 hours in normal male Sprague Dawley rats compared with hGRF(1-29)[1]. | Rat experiment and pituitary-cell work, not a human outcome study. | PubMed lists no grant; the author affiliation is ConjuChem. | 2026-08-30 |
| [1] | CJC-1295 was present in rat plasma beyond 72 hours. Western blot found an albumin-band signal after 15 minutes and beyond 24 hours. | The pharmacokinetic finding is preclinical. | PubMed lists no grant; the author affiliation is ConjuChem. | 2026-08-30 |
| [5] | FDA identified repeated-dose injection-site hemorrhage, inflammation, and necrosis in rats and dogs treated with daily subcutaneous CJC-1295 DAC at doses of at least 0.25 mg/kg for up to 14 days[5]. | Nonclinical toxicology does not give a human incidence rate. | US regulator review. | 2026-08-30 |
| [5] | FDA says it did not identify two-year carcinogenicity studies for the CJC-1295-related substances it evaluated[5]. | This is a study-absence finding, not a tumor-rate finding. | US regulator review. | 2026-08-30 |
The preclinical findings support the identity story: DAC was designed to extend albumin-linked exposure. They do not show that no-DAC labels carry the same evidence base.
What has direct vial or product testing found?
Direct tests ask what was in a sample. They do not prove a human result. A label is a claim. A test is a check. The opened CJC-1295 records include one product ID paper and one large preprint built from submitted lab reports.
| Source | What was measured | What was not measured | Funder note | Checked |
|---|---|---|---|---|
| [17] | A 2009 unknown pharmaceutical preparation submitted by Norwegian police and customs authorities contained a 29-amino-acid peptide with a C-terminal amide[17]. The proposed sequence was consistent with a peptide marketed under the CJC-1295 name. | One unknown preparation cannot describe the wider market. The abstract gives no month for the 2009 submission. | PubMed XML lists no grant. | 2026-08-30 |
| [18] | The preprint says its methods included 6,487 analysis reports across 14 peptides and 156 identity failures, including CJC-1295 N=22[18]. | The data came from submitted reports, not a random market survey. | The manuscript states no external funding and no conflicts of interest. | 2026-08-30 |
| [18] | The preprint reports CJC-1295 median purity of 98.49%, with an interquartile range of 91.59% to 99.60%[18]. | The manuscript page states that the version has not been peer reviewed. | The manuscript states no external funding and no conflicts of interest. | 2026-08-30 |
| [18] | Across the full dataset's endotoxin subset, 74 samples had no detectable endotoxin, 133 were below the lower limit, and 36 had low measurable endotoxin between 0.5 and 40 EU/mL[18]. | The opened text does not state a CJC-1295-only endotoxin count. | The manuscript states no external funding and no conflicts of interest. | 2026-08-30 |
The vial-testing guide separates identity, amount, purity, endotoxin, and sterility questions. The sterility guide covers the sterile-use question that purity testing does not answer.
What do user reports add?
User reports are public self-reports. They show real speech from users. The users choose to post them. They describe effects, timing, combinations, and product labels that controlled papers often do not study. They are not lab proof. They are not counted here as consensus.
Van Hout and Hearne searched for CJC-1295 plus forum terms. Their final set had 23 female-use threads[2]. The authors found talk about weight loss, muscle, skin, sleep, and injury healing. That paper studies forum speech, not CJC-1295 treatment.
The opened ExcelMale thread follows one 2014 account using products labelled CJC-1295 without DAC and ipamorelin, later adding a DAC-labelled exposure[19]. The user wrote "Workouts are excellent" after the first report and "could NOT sleep" after a pre-bed report. Later posts described strength gains, flushing, and changing amounts. No laboratory report in the thread confirms either product.
One r/Peptidesource thread dated 27 February 2025 shows the same mix of positive and adverse self-reports[20]. These are direct Reddit quotes from opened comments, linked so the whole thread remains visible.
Everything works better on CJC/Ipa. Immune system, recovery, sex drive, deeper sleep, cognitive function, skin glow, hair.
I loved it!! I did 2 3-month cycles last year, and I had great consistent energy, very fast recovery from the gym, very noticeable muscle gains while losing 15lbs of fat, great sleep, great skin, enhanced cognitive function, much better mood. 41yo F
Not for me- I had an allergic reaction to CJC-1295 (widespread rash) that took a steroid to go away, and MOTS-C which I loved, but caused a big itchy welt after a few weeks of use.
There is no single verdict from these posts. People report energy, recovery, sleep, body changes, flushing, insomnia, and rash. The page keeps those reports apart from the measured GH and IGF-I trials.
What is the current evidence status, and what is the regulatory status?
Evidence tier, product-label status, compounding status, and trial status are different flags. A regulator zero is not the same thing as a human-evidence absence. A trial result is not an approval.
| Question | Current answer | Source and limit | Checked |
|---|---|---|---|
| Evidence tier | CJC-1295 has tier B human evidence because randomized human clinical papers exist[3]. | The trial results are hormone and pharmacokinetic results in healthy adults. | 2026-08-30 |
| DAC versus no-DAC | The US FDA evaluates CJC-1295 free base and CJC-1295 DAC free base as different active moieties[5]. FDA says the clinical references appear to refer to CJC-1295 DAC free base but do not specify a salt. | The public trial names do not make every vial label reliable. | 2026-08-30 |
| Controlled combo evidence | No controlled CJC-1295 plus ipamorelin clinical publication is cited here. | The exact-name PubMed clinical-trial search returned only PMID 17018654 and PMID 16352683[4]. | 2026-08-30 |
| Registered trial | NCT00267527 is terminated, enrolled 120 people, names HIV-associated visceral obesity, lists ConjuChem as sponsor, and posts no results[12]. | The record gives no stopping reason. | 2026-08-30 |
| FDA product-label search | DailyMed's exact CJC-1295 search returned zero current labels[14]. | Exact-name label search only. | 2026-08-30 |
| FDA application search | The exact openFDA brand-name search for CJC-1295 returned no matching application[15]. | Exact brand-name application search only. | 2026-08-30 |
| FDA compounding status | FDA lists CJC-1295 in the withdrawn-nominations table on its current compounding safety-risk page[13]. | This is a US pharmacy-compounding source, not a global regulatory status. | 2026-08-30 |
| EMA central medicines report | The EMA medicines report generated on 30 August 2026 at 18:00 had 2,732 medicine rows and no CJC-1295, CJC 1295, or mod-GRF 1-29 hit[16]. | This checks the central EU route, not every national route. | 2026-08-30 |
| Product circulation | Henninge et al. reported an unknown preparation submitted in 2009 and identified a sequence consistent with a peptide marketed as CJC-1295[17]. | The paper gives no month for the 2009 submission. | 2026-08-30 |
The data file is /data/register.json.
See also
- Full CJC-1295 guide - read the earlier guide and same-compound background.
- Training and recovery hub - compare human evidence across related recovery compounds.
- Vial-testing guide - separate label identity from measured contents.
- Sterility guide - separate purity tests from sterile-use questions.
- Ipamorelin register record - read the other compound named in the main user-report thread.
- Modified GRF 1-29 register record - read the no-DAC-related register record separately.
- Sermorelin register record - compare another GHRH-pathway compound.
FAQ
Is CJC-1295 DAC the same as CJC-1295 no DAC?
No. The US FDA treats CJC-1295 free base and CJC-1295 DAC free base as different active moieties[5]. FDA also says the clinical references appear to involve CJC-1295 DAC free base, with the salt unspecified.
What is CJC-1295 with ipamorelin good for?
The controlled CJC-1295 papers measured GH, IGF-I, GH pulses, blood levels, and safety[3]. Forum accounts describe energy, recovery, sleep, skin, mood, fat loss, and rash[20]. Those posts did not include lab proof of the products.
How long does it take to see results from CJC-1295 and ipamorelin?
Teichman measured GH elevation for at least 6 days after one CJC-1295 injection[3]. IGF-I rose for 9 to 11 days. One ExcelMale user reported workout changes within days and strength comments after one month[19]. That thread combined CJC labels with ipamorelin.
What are the downsides of CJC-1295?
FDA lists injection-site reactions, headache, diarrhea, flushing, low blood pressure, increased heart rate, and limited clinical data[5]. The healthy-adult trial abstract reported no serious adverse reactions[3]. FDA separately describes one death in anecdotal unpublished HIV-study reports[5].
Does CJC-1295 suppress testosterone?
No cited human CJC-1295 trial here measured testosterone suppression. Teichman measured GH, IGF-I, pharmacokinetics, and safety[3]. Ionescu and Frohman measured overnight GH pulsatility and IGF-I one week after dosing[10].
Does CJC-1295 help with weight loss?
Van Hout and Hearne found weight-loss aims in CJC-1295 forum discussions[2]. The exact-name controlled clinical papers cited here measured hormones and pharmacokinetics, not a published weight-loss outcome[4].
Does CJC-1295 come in tablet or oral form?
No cited human CJC-1295 clinical paper here studied an oral or tablet product. Teichman's clinical-trial abstract says CJC-1295 or placebo was administered subcutaneously[3]. The current DailyMed exact search returned no CJC-1295 label[14].
References
- ↑ a b c d e f g h Jetté L et al. CJC-1295 rat albumin study. Endocrinology, 2005. PMID 15817669. DOI 10.1210/en.2004-1286. Used for identity and albumin-binding design. Used for rat GH AUC and rat plasma duration. ConjuChem affiliation checked 2026-08-30.
- ↑ a b c d e Van Hout MC, Hearne E. CJC-1295 female forum netnography. Subst Use Misuse, 2016. PMID 26771670. DOI 10.3109/10826084.2015.1082595. Used for forum method and 23 threads. Used for claimed-use themes. No grant in PubMed XML; checked 2026-08-30.
- ↑ a b c d e f g h i j k l m n o p q Teichman SL et al. CJC-1295 healthy-adult GH trial. J Clin Endocrinol Metab, 2006. PMID 16352683. DOI 10.1210/jc.2005-1536. Used for trial design, GH, IGF-I, half-life, route, and schedule shape. Used for the no-serious-adverse-reaction statement. Funded by ConjuChem, Inc. (DOI
10.1210/jc.2005-1536; funding checked 2026-09-05). - ↑ a b c d e f National Library of Medicine. Exact PubMed clinical-trial search for CJC-1295, run 2026-08-30. Used for the bounded clinical-trial-search absence. Used for the two-record result. Checked 2026-08-30.
- ↑ a b c d e f g h i j k l m n o p q r United States FDA. CJC-1295 PCAC briefing. FDA, 2024. FDA briefing PDF. Used for DAC/no-DAC split and study-form uncertainty. Used for ConjuChem manufacture, dose arms, safety findings, nonclinical findings, approval-component status, and the unpublished HIV-study account. Checked 2026-08-30.
- ↑ a b NCATS GSRS. CJC-1295 substance record, UNII 62RC32V9N7. GSRS 62RC32V9N7. Used for display name, sequence, length, UUID, and UNII. Checked 2026-08-30.
- ↑ NCATS GSRS. CJC-1295 names endpoint. GSRS names. Used for recorded names. Checked 2026-08-30.
- ↑ a b NCATS GSRS. CJC-1295 codes endpoint. GSRS codes. Used for UNII, CAS, RXCUI, and PubChem. Checked 2026-08-30.
- ↑ a b NCATS GSRS. CJC-1295 properties endpoint. GSRS properties. Used for molecular formula and weight. Checked 2026-08-30.
- ↑ a b c d e f g h Ionescu M, Frohman LA. CJC-1295 GH pulsatility study. J Clin Endocrinol Metab, 2006. PMID 17018654. DOI 10.1210/jc.2006-1702. Used for the 12-man study, 60/90 microg/kg dose, GH, IGF-I, and safety. NIH grant checked 2026-08-30.
- ↑ a b Sackmann-Sala L et al. CJC-1295 serum protein-profile study. Growth Horm IGF Res, 2009. PMID 19386527. DOI 10.1016/j.ghir.2009.03.001. Used for the 11-person reanalysis and changed protein spots. NIH grants checked 2026-08-30.
- ↑ a b c d e ConjuChem. CJC 1295 in HIV visceral obesity. ClinicalTrials.gov. NCT00267527. Used for registry status, condition, sponsor, enrollment, missing stopping reason, and no results. Checked 2026-08-30.
- ↑ a b c United States FDA. Compounding substances with safety-risk concerns. FDA. FDA compounding page. Used for withdrawn-nominations status and current US wording. Checked 2026-08-30.
- ↑ a b c d National Library of Medicine. DailyMed exact search for CJC-1295. Used for US label-search absence. Checked 2026-08-30.
- ↑ United States FDA. openFDA exact brand-name search for CJC-1295. Used for brand-name application-search absence. Checked 2026-08-30.
- ↑ European Medicines Agency. Medicines output report, generated 2026-08-30 18:00. EMA medicines report. Used for central EU register absence and row count. Checked 2026-08-30.
- ↑ a b c Henninge J et al. CJC-1295 unknown-product identification. Drug Test Anal, 2010. PMID 21204297. DOI 10.1002/dta.233. Used for unknown-product identification, 2009 submission, proposed sequence, product-circulation limit, and no-grant note. Checked 2026-09-05.
- ↑ a b c d e f Mendias CL, Awan TM. Research-grade peptide testing preprint. Preprints.org, 2026. Preprint manuscript. Used for report counts, identity failures, CJC-1295 purity, endotoxin subset, review status, funding, and conflicts. Checked 2026-08-30.
- ↑ a b c d e Mike Jason Pascual. Ipamorelin and CJC-1295 w/o DAC account. ExcelMale, 2014. ExcelMale thread. Used for one self-report, source-reported amounts, timing, sleep, workouts, flushing, and product-verification limit. Checked 2026-08-30.
- ↑ a b c d Reddit users. Not every Peptide is for You!. r/Peptidesource, 2025. Reddit thread. Used for opened direct self-reports on CJC/Ipa positives and rash. Checked 2026-08-30.